Fontolizumab

Fontolizumab
Monoclonal antibody
Type	; Whole antibody
Source	; Humanized (from mouse)
Target	; interferon gamma;
Clinical data
ATC code	; none; ;
Identifiers
CAS Number	; ; 326859-36-3 N; ;
ChemSpider	; none; ;
UNII	; 6J92H2439Z; ;
KEGG	; ; D04242 Y; ;
Chemical and physical data
Molar mass	; ca. 150 kg/mol
; NY (what is this?) (verify);

Fontolizumab (planned trade name HuZAF) is a humanized monoclonal antibody^[1] and an immunosuppressive drug for the treatment of auto-immune diseases like Crohn's disease.^[2] A phase II clinical trial investigating the use for rheumatoid arthritis was terminated because the first phase did not meet the endpoint.^[3]

References[edit]

^ Statement On A Nonproprietary Name Adopted By The Usan Council - Fontolizumab, American Medical Association.

^ Reinisch, W; De Villiers, W; Bene, L; Simon, L; Rácz, I; Katz, S; Altorjay, I; Feagan, B; et al. (2009). "Fontolizumab in moderate to severe Crohn's disease: A phase 2, randomized, double-blind, placebo-controlled, multiple-dose study". Inflammatory bowel diseases. 16 (2): 233–42. doi:10.1002/ibd.21038. PMID 19637334..mw-parser-output cite.citationfont-style:inherit.mw-parser-output qquotes:"""""""'""'".mw-parser-output code.cs1-codecolor:inherit;background:inherit;border:inherit;padding:inherit.mw-parser-output .cs1-lock-free abackground:url("//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png")no-repeat;background-position:right .1em center.mw-parser-output .cs1-lock-limited a,.mw-parser-output .cs1-lock-registration abackground:url("//upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png")no-repeat;background-position:right .1em center.mw-parser-output .cs1-lock-subscription abackground:url("//upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png")no-repeat;background-position:right .1em center.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registrationcolor:#555.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration spanborder-bottom:1px dotted;cursor:help.mw-parser-output .cs1-hidden-errordisplay:none;font-size:100%.mw-parser-output .cs1-visible-errorfont-size:100%.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-formatfont-size:95%.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-leftpadding-left:0.2em.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-rightpadding-right:0.2em

^ Clinical trial number NCT00281294 for "A Phase 2 Study to Evaluate the Safety, Tolerability, and Activity of Fontolizumab in Subjects With Active Rheumatoid Arthritis" at ClinicalTrials.gov

This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

[1] Statement On A Nonproprietary Name Adopted By The Usan Council - Fontolizumab, American Medical Association.

[2] Reinisch, W; De Villiers, W; Bene, L; Simon, L; Rácz, I; Katz, S; Altorjay, I; Feagan, B; et al. (2009). "Fontolizumab in moderate to severe Crohn's disease: A phase 2, randomized, double-blind, placebo-controlled, multiple-dose study". Inflammatory bowel diseases. 16 (2): 233–42. doi:10.1002/ibd.21038. PMID 19637334..mw-parser-output cite.citationfont-style:inherit.mw-parser-output qquotes:"""""""'""'".mw-parser-output code.cs1-codecolor:inherit;background:inherit;border:inherit;padding:inherit.mw-parser-output .cs1-lock-free abackground:url("//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png")no-repeat;background-position:right .1em center.mw-parser-output .cs1-lock-limited a,.mw-parser-output .cs1-lock-registration abackground:url("//upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png")no-repeat;background-position:right .1em center.mw-parser-output .cs1-lock-subscription abackground:url("//upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png")no-repeat;background-position:right .1em center.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registrationcolor:#555.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration spanborder-bottom:1px dotted;cursor:help.mw-parser-output .cs1-hidden-errordisplay:none;font-size:100%.mw-parser-output .cs1-visible-errorfont-size:100%.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-formatfont-size:95%.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-leftpadding-left:0.2em.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-rightpadding-right:0.2em

[3] Clinical trial number NCT00281294 for "A Phase 2 Study to Evaluate the Safety, Tolerability, and Activity of Fontolizumab in Subjects With Active Rheumatoid Arthritis" at ClinicalTrials.gov

搜尋此網誌

njtynhj

Fontolizumab

Fontolizumab

References[edit]

Navigation menu

Personal tools

Namespaces

Variants

Views

More

Search

Navigation

Interaction

Tools

Print/export

Languages

Popular posts from this blog

The Dalles, Oregon

眉山市

清晰法令

Monoclonal antibody
Type	Whole antibody
Source	Humanized (from mouse)
Target	interferon gamma
Clinical data
ATC code	none
Identifiers
CAS Number	326859-36-3^N
ChemSpider	none
UNII	6J92H2439Z
KEGG	D04242^Y
Chemical and physical data
Molar mass	ca. 150 kg/mol
^NY (what is this?) (verify)